Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Non-Current Assets (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Non-Current Assets for 11 consecutive years, with $7.2 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Non-Current Assets fell 19.76% year-over-year to $7.2 million, compared with a TTM value of $29.8 million through Jun 2025, down 16.75%, and an annual FY2024 reading of $6.8 million, down 24.46% over the prior year.
  • Non-Current Assets was $7.2 million for Q2 2025 at Kiora Pharmaceuticals, up from $6.8 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $13.7 million in Q2 2021 and bottomed at -$11.7 million in Q3 2021.
  • Average Non-Current Assets over 5 years is $8.6 million, with a median of $9.9 million recorded in 2023.
  • The sharpest move saw Non-Current Assets tumbled 303.97% in 2021, then surged 194.15% in 2022.
  • Year by year, Non-Current Assets stood at $11.1 million in 2021, then fell by 0.91% to $11.0 million in 2022, then dropped by 18.7% to $9.0 million in 2023, then dropped by 24.46% to $6.8 million in 2024, then grew by 6.34% to $7.2 million in 2025.
  • Business Quant data shows Non-Current Assets for KPRX at $7.2 million in Q2 2025, $6.8 million in Q4 2024, and $6.9 million in Q3 2024.